Skip to content

Ex Vivo Expanded Erythroblast-Transplantation (Autologous) study

Ex Vivo Expanded Erythroblast-Transplantation (Autologous) study - EVEETA study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTb030190188
Enrollment
11
Registered
2020-01-16
Start date
2018-02-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic clitical limb ischemia

Interventions

Bone marrow cells collected from the patient are cultured outside the body for 14 days.Mainly consists of amplified autologous erythroblasts, and bone marrow-derived mesenchymal cells are suspended in

Sponsors

Minamino Tohru
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with peripheral artery disease (ASO/Burger disease/vasculitis with collagen disease) 1. Fontaine grade 3-4 (rest pian or ischemic ulcer/necrosis). 2. markedly impaired QOL who are not indicated for revascularization and who are expected to undergo amputation in the future, or who have poor blood flow even after revascularization (skin perfusion pressure less than 40mmHg), and cannot recovery from severe limb ischemia.

Exclusion criteria

Exclusion criteria: 1. Patients who have a life expectancy of less than one year due to complications. 2. Patients with a history of alcohol or drug dependence within the past 3 months. 3. Patients with a malignant neoplasm or have had a history within 5 years, or patients who have been determined to have a malignant tumor by other prescribed tests. 4. Patients with proliferative diabetic retinopathy (untreated proliferative retinopathy, intermediate / late proliferative retinopathy). 5. Polycythemic patients with hematocrit values of 55% or more in men and 50% or more in women. 6. Patients who cannot obtain informed consent. 7. Patients with active and moderate infection, HIV / HBV / HCV positive, and active Treponema pallidum infection. 8. Patients suffering from acute myocardial infarction, unstable angina, myocarditis, cerebral infarction within 1 month of consent.

Design outcomes

Primary

MeasureTime frame
Change in skin perfusion pressure (SPP)

Secondary

MeasureTime frame
1. avoidance rate of lower limb amputation 2. cardiovascular event (cardiac death, non-fatal myocardial infarction, revascularization, stroke) 3. Perioperative complications 4. Symptom improvement(VAS) 5. change of lower limbs ulcer size

Countries

Japan

Contacts

Public ContactTakao Yanagawa

Niigata University Medical and Dental General Hospital

takao-ya@med.niigata-u.ac.jp+81-25-227-2185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026